SUNRIDGE MEDICAL • INTEGRATIVE ONCOLOGY
Mistletoe Extract and Cancer: Viscum album, Quality of Life & Integrative Oncology Research
Mistletoe extract is one of the most extensively studied complementary cancer therapies in Europe, with research spanning quality of life, treatment tolerance, immune signaling, apoptosis, lung cancer, breast cancer, pancreatic cancer, colorectal cancer and advanced solid tumors.
European mistletoe—Viscum album L.—contains biologically active lectins, viscotoxins, polysaccharides and other compounds that have been studied for effects on tumor cells and immune signaling.
At Sunridge Medical in Scottsdale, Arizona, mistletoe may be considered as part of a physician-directed integrative cancer treatment program when appropriate for the individual patient.
The current evidence is complex. Some clinical studies report improvements in quality of life or treatment-related symptoms, while survival results are inconsistent and newer high-quality pancreatic-cancer data have challenged earlier positive findings. This page reviews that evidence directly rather than treating every mistletoe study as equivalent.
European mistletoe (Viscum album) is the source of multiple standardized extracts studied in integrative oncology.
EUROPEAN MISTLETOE • VISCUM ALBUM
What Is Mistletoe Extract?
Mistletoe extract used in oncology is generally prepared from European mistletoe, Viscum album L., a semiparasitic plant that grows on several host trees.
The National Cancer Institute identifies mistletoe as one of the most widely studied complementary and alternative therapies in cancer care and notes that injectable Viscum album preparations are widely used in parts of Europe.1
Mistletoe products are not all the same. Their chemical composition can vary according to host tree, harvest season, manufacturing method, fermentation and producer.1
DIFFERENT EXTRACTS • DIFFERENT CHEMISTRY
Iscador, Helixor, abnobaVISCUM and Host-Tree Differences
Several mistletoe preparations have been studied clinically, including Iscador, Helixor and abnobaVISCUM.
NCI describes multiple host-tree-specific preparations. For example, Iscador products may be derived from apple, pine, oak or elm, while Helixor preparations include extracts from spruce, apple and pine.1
These differences matter because mistletoe lectin content, viscotoxins and other constituents can vary. A study performed with one commercial preparation should not automatically be treated as evidence for every mistletoe product.
LECTINS • VISCOTOXINS • POLYSACCHARIDES
The Biologically Active Components of Mistletoe
Three groups of compounds receive particular attention in mistletoe research: mistletoe lectins, viscotoxins and polysaccharides.
NCI describes mistletoe lectins as complex protein-carbohydrate molecules capable of binding to cell surfaces and producing biochemical changes. Viscotoxins are smaller proteins with direct cell-killing activity in experimental systems.1
The concentration of these compounds varies among preparations, which is another reason mistletoe therapy is more pharmacologically complex than simply using an herbal tea or generic plant capsule.
PROGRAMMED CELL DEATH
Mistletoe Lectins, Viscotoxins and Apoptosis
One of the central preclinical mechanisms studied with mistletoe is apoptosis, or programmed cell death.
NCI’s evidence review cites laboratory studies in which mistletoe extracts and mistletoe lectins demonstrated cytotoxicity toward tumor cells through induction of apoptosis.1
Mistletoe components have also been studied in relation to caspases, mitochondrial pathways, cell-cycle signaling and ribosomal protein synthesis.
These mechanisms provide a biologic rationale for oncology research, but laboratory apoptosis does not by itself establish clinical efficacy in patients.
IMMUNE SIGNALING
Mistletoe as a Biological Response Modifier
Mistletoe has historically been described as a biological response modifier because experimental research shows effects on immune cells.
NCI summarizes preclinical findings involving natural-killer-cell-mediated tumor lysis, stimulation of immune cells and other immunologic changes.1
At the same time, NCI specifically notes that there is no evidence proving that mistletoe-induced immune stimulation translates into an improved ability to fight cancer in patients.1
This distinction is important: measurable immune activity and proven anticancer benefit are not the same endpoint.
INVASION • ANGIOGENESIS • TUMOR BIOLOGY
Migration, Invasion and Angiogenesis Research
Mistletoe research extends beyond apoptosis and immune signaling.
NCI reports preclinical evidence that mistletoe extracts can reduce tumor-cell migration and invasion and can influence genes involved in malignant progression, including TGF-β and matrix metalloproteinases. Antiangiogenic effects have also been described experimentally.1
These observations help explain why mistletoe continues to attract interest as a multi-component integrative oncology therapy.
Mistletoe has been studied most often by subcutaneous injection, while intravenous and other routes have also been investigated.
ROUTE OF ADMINISTRATION
Subcutaneous, Intravenous and Other Mistletoe Routes
Most published mistletoe studies use subcutaneous injection. NCI notes that other routes—including oral, intrapleural, intratumoral and intravenous administration—have also been described.1
The route should not be treated as a minor detail. Different administration routes create different exposure, safety considerations and evidence bases.
The strongest modern U.S. intravenous data come from a small phase I trial of IV Helixor M in heavily pretreated patients with advanced solid tumors.2
U.S. PHASE I RESEARCH
Intravenous Mistletoe in Advanced Solid Tumors
A 2023 phase I trial evaluated intravenous Helixor M in 21 patients with advanced solid tumors that had progressed after at least one prior therapy.2
The purpose was primarily to determine safety and dosing, not to prove efficacy. No objective responses were reported. Five patients had stable disease, for a disease-control rate of 23.8%, and quality-of-life scores improved during the early treatment period.
The study established a maximum tolerated dose for the tested schedule and found generally manageable toxicities, supporting further phase II research rather than establishing IV mistletoe as a proven anticancer treatment.
QUALITY OF LIFE
What the Quality-of-Life Research Shows
Quality of life is one of the strongest recurring themes in mistletoe research.
A 2020 systematic review and meta-analysis included 26 publications with 30 data sets and reported a medium-sized improvement in global quality of life with mistletoe compared with control. Pain, nausea and other subdomains improved in a portion of studies.3
However, many of the included studies had a high risk of bias or raised methodological concerns. NCI likewise notes that quality-of-life benefits are frequently reported but that study quality varies substantially.1
SURVIVAL EVIDENCE
Why the Survival Evidence Is More Controversial
NCI’s review states that many clinical studies have reported survival benefits, but substantial methodological weaknesses reduce confidence in those findings. A 2019 systematic review concluded that most studies did not demonstrate a survival effect and that higher-quality studies were less likely to show benefit.4
For a credible integrative oncology page, mistletoe should therefore be discussed separately as a therapy with possible supportive benefits and as a therapy with uncertain survival effects.
NON-SMALL CELL LUNG CANCER
Mistletoe and Lung Cancer
A randomized phase II study evaluated Iscador together with carboplatin-based chemotherapy in 72 patients with advanced non-small cell lung cancer.9
Median overall survival was 11 months in both groups. Time to progression was not significantly different, and there was demonstrated quality-of-life benefit.
However, chemotherapy dose reductions, severe non-hematologic toxicities and hospitalizations were less frequent in the mistletoe group. The authors concluded that these findings warranted additional investigation of mistletoe as a modifier of chemotherapy-related toxicity.9
BREAST CANCER
Mistletoe During Breast Cancer Chemotherapy
Breast cancer is among the most frequently studied cancer types in the mistletoe literature.
A randomized early-stage breast-cancer study reported better quality-of-life scores during CAF chemotherapy in patients who also received Viscum album extract. Five-year follow-up found no meaningful difference in relapse or metastasis frequency between the mistletoe and control groups.10
That combination of findings is clinically important: mistletoe may be studied as supportive care during treatment without implying that it reduces recurrence.
A 2025 UK pilot study also examined the feasibility of a modern placebo-controlled double-blind mistletoe trial in breast cancer, reflecting continuing interest in improving the quality of evidence.11
COLORECTAL CANCER
Mistletoe and Metastatic Colorectal Cancer
A phase II trial evaluated subcutaneous abnobaVISCUM in 25 patients with metastatic colorectal cancer resistant to 5-FU/leucovorin-based chemotherapy.12
No objective tumor responses were observed. Stable disease occurred in 21 patients for a median of 12.5 months, and 40% reported symptomatic relief.
Other colorectal studies have focused more on quality of life, perioperative use and treatment-related symptoms, but the direct objective-response data should not be overlooked.
MALIGNANT MELANOMA
Mistletoe and Melanoma
Melanoma has been studied primarily in older cohort and controlled research.
A long-term study of patients with stage II–III malignant melanoma reported that fermented mistletoe treatment appeared safe and was associated with favorable survival outcomes compared with untreated controls, but the authors explicitly stated that the results required confirmation in a prospective randomized trial with an improved design.13
Because modern melanoma treatment has changed dramatically with checkpoint inhibitors and targeted therapies, older mistletoe survival observations need to be interpreted in their historical treatment context.
GASTRIC & GYNECOLOGIC CANCERS
Mistletoe Research Beyond the Major Cancer Types
Mistletoe has also been studied in gastric, ovarian, gynecologic and other cancers.
NCI cites a randomized pilot study in gastric cancer that evaluated quality of life, immunomodulation and safety after surgery.1 A prospective randomized study also evaluated complementary mistletoe in patients with breast, ovarian and non-small cell lung cancer, focusing on quality of life during chemotherapy.14
The broader literature reinforces an important pattern: supportive-care outcomes are studied more consistently than durable tumor responses.
MALIGNANT PLEURAL EFFUSION
Mistletoe and Pleural Effusion in Lung Cancer
Mistletoe preparations have also been studied locally in patients with malignant pleural effusion, including lung-cancer populations.
NCI’s review includes clinical studies of intrapleural mistletoe and pleurodesis using abnobaVISCUM.1
This is a different clinical use from systemic subcutaneous mistletoe therapy and should not be presented as equivalent evidence.
BLADDER CANCER
Mistletoe in Bladder Cancer Research
A phase Ib/IIa single-group dose-escalation study evaluated mistletoe plant extract in patients with nonmuscle-invasive bladder cancer.15
This adds bladder cancer to the list of tumors in which mistletoe has undergone direct clinical investigation, although the study design was exploratory and not a definitive randomized efficacy trial.
SAFETY
Mistletoe Side Effects and Local Reactions
Subcutaneous mistletoe frequently produces local inflammatory reactions such as redness, warmth, swelling or itching at the injection site.
Systemic symptoms such as fever, chills, fatigue, headache or flu-like symptoms can also occur. Serious allergic reactions are uncommon but have been reported.1
NCI notes that relatively few serious adverse effects have been associated with mistletoe extract use overall, but the safety profile depends on preparation, dose, route and patient characteristics.
AUTOIMMUNE & IMMUNE-DIRECTED THERAPY
Why Immune History Matters
Because mistletoe can alter cytokine and immune-cell activity, the patient’s immune history matters.
Autoimmune disease, immune-modulating medications, checkpoint-inhibitor therapy and transplant-related immunosuppression can all change the clinical context.
Mistletoe should therefore not be selected solely because a patient wants to “boost the immune system.” The relevant question is how immune modulation fits with the specific cancer treatment being used.
CHEMOTHERAPY & RADIATION
Can Mistletoe Be Used During Conventional Cancer Treatment?
Many mistletoe studies have evaluated the extract as an add-on to chemotherapy, radiation or other cancer care rather than as a replacement.
Laboratory research has generally not shown inhibition of chemotherapy-induced cytotoxicity across several tested drug combinations, and some clinical studies have focused specifically on treatment tolerance.16
That does not mean every drug combination is proven safe. The exact chemotherapy, targeted therapy, immunotherapy and mistletoe preparation still require physician review.
U.S. REGULATORY STATUS
Mistletoe in the United States
European mistletoe products are commonly prescribed as injectable drugs in several European countries.
In the United States, NCI states that injectable mistletoe products are not FDA-approved as a cancer treatment and are not commercially available in the same way as European prescription mistletoe drugs.1
THE SUNRIDGE APPROACH
Mistletoe in a Physician-Directed Integrative Oncology Program
At Sunridge Medical, mistletoe may be considered within a broader cancer-treatment strategy rather than as an isolated protocol.
Clinical considerations can include:
- Cancer type and stage
- Current chemotherapy, immunotherapy, targeted therapy or radiation
- Autoimmune history
- Blood counts and organ function
- Current medications
- Previous treatment tolerance
- The specific mistletoe preparation and route
- Quality-of-life and symptom goals
- Other botanical, metabolic and intravenous therapies being used
The goal is to match the treatment strategy to the patient instead of assuming that every person with cancer should receive the same mistletoe preparation.
FREQUENTLY ASKED QUESTIONS
Frequently Asked Questions About Mistletoe Extract and Cancer
What is mistletoe extract?
Oncology mistletoe preparations are generally made from European mistletoe, Viscum album L. Products vary by host tree, manufacturing method, fermentation and biologically active constituents.
What are mistletoe lectins?
Mistletoe lectins are protein-carbohydrate molecules that can bind to cell surfaces and produce biological effects. They are among the most studied active components of mistletoe.
How is mistletoe usually given in cancer care?
Most clinical studies have used subcutaneous injections. Intravenous, intratumoral, intrapleural and other routes have also been studied.
Does mistletoe improve cancer survival?
The survival evidence is inconsistent. Some older studies reported benefits, but methodological concerns are common and higher-quality studies have not consistently confirmed a survival advantage.
Does mistletoe improve quality of life?
Quality-of-life improvement is one of the more consistent findings in mistletoe research, although many studies still carry risk of bias.
What did the newest pancreatic cancer trial find?
A placebo-controlled randomized trial published in 2024 did not find a statistically significant overall-survival or global quality-of-life benefit from adding mistletoe to standard treatment in advanced pancreatic cancer.
Has mistletoe been studied in lung cancer?
Yes. A randomized phase II trial in advanced NSCLC found the same median overall survival in both groups but fewer chemotherapy dose reductions, severe non-hematologic toxicities and hospitalizations in the mistletoe group.
Has mistletoe been studied in breast cancer?
Yes. Some studies reported better quality of life during chemotherapy, while five-year follow-up did not show a clear difference in relapse or metastasis.
Does Sunridge Medical use mistletoe?
Mistletoe may be considered within individualized physician-directed integrative oncology programs when clinically appropriate.
BECOME A PATIENT
Explore Physician-Directed Mistletoe Therapy and Integrative Cancer Care
Mistletoe has a larger clinical literature than many complementary cancer therapies, but the evidence varies substantially by cancer type, outcome, product and study design.
Speak with our Patient Care Team about your diagnosis, current treatment and whether mistletoe may fit within a broader integrative oncology strategy.
RESEARCH
References
- National Cancer Institute. Mistletoe Extracts (PDQ®) – Health Professional Version. NCI evidence review of preparations, mechanisms, routes, clinical studies, safety and regulatory status.
- Paller CJ, et al. Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Cancer Research Communications. 2023. PMID: 36860652.
- Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. 2020. PMID: 32690087.
- Freuding M, et al. Mistletoe in oncological treatment: a systematic review. Part 1: survival and safety. 2019. PMID: 30673873.
- Tröger W, et al. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomized clinical trial on overall survival. European Journal of Cancer. 2013. PMID: 23890767.
- Tröger W, et al. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. 2014. PMID: 25142075.
- Wode K, et al. Mistletoe Extract in Patients With Advanced Pancreatic Cancer: a placebo-controlled randomized clinical trial. 2024. PMID: 38915151.
- Vella R, et al. Unconventional Treatments for Pancreatic Cancer: A Systematic Review. 2025. PMID: 40361364.
- Bar-Sela G, et al. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. European Journal of Cancer. 2013. PMID: 23218588.
- Tröger W, et al. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album extract to chemotherapy alone. PMID: 23150723.
- Duncan LJ, et al. The Mistletoe and Breast Cancer (MAB) Study: a UK pilot randomized placebo-controlled trial feasibility study. 2025. PMID: 41097697.
- Bar-Sela G, Haim N. Abnoba-viscum in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. 2004. PMID: 15456952.
- Augustin M, et al. Safety and efficacy of long-term adjuvant treatment with a standardized fermented European mistletoe extract in high-risk malignant melanoma. 2005. PMID: 15727163.
- Piao BK, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients: a prospective randomized controlled trial. 2004. PMID: 15015612.
- Rose A, et al. Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study. 2015. PMID: 25910967.
- Weissenstein U, et al. Interaction of standardized mistletoe extract with chemotherapeutic drugs in vitro. 2014. PMID: 24397864.
